Results 231 to 240 of about 10,488 (304)

Control survey of radioimmunoassay-.ALPHA.-fetoprotein and a study on reference standard.

open access: bronze, 1985
Kyoko Shibata   +3 more
openalex   +2 more sources

Recurrent Remitting Seronegative Symmetrical Synovitis With Pitting Edema in a Nonagenarian: An Atypical Clinical Course Requiring Methotrexate for Remission

open access: yesJournal of General and Family Medicine, Volume 27, Issue 1, January 2026.
ABSTRACT Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome is a rare inflammatory arthritis of older adults. We report a 92‐year‐old man who presented with fatigue and distal pitting edema, fulfilling the clinical features of RS3PE.
Ken Sato
wiley   +1 more source

Assessment of Circulating Tumor DNA for Early Detection of Hepatocellular Carcinoma in Alpha‐Fetoprotein–Negative Patients With Cirrhotic Nodules

open access: yesJGH Open, Volume 10, Issue 1, January 2026.
ABSTRACT Aims Early detection is essential for improving hepatocellular carcinoma's (HCC) prognosis. However, the diagnostic performance of the current interventions remains unsatisfactory, particularly in patients with cirrhotic nodules. We aimed to develop a predictive model for the early detection of HCC using circulating tumor DNA (ctDNA) profiles ...
Li‐Jun Chang   +6 more
wiley   +1 more source

The Expression of Alpha-Fetoprotein in Human Blastocoel Fluid-Conditioned Media In Vitro: A Proof of Concept Study. [PDF]

open access: yesInt J Mol Sci
Kavoussi SK   +8 more
europepmc   +1 more source

Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab

open access: yesJGH Open, Volume 10, Issue 1, January 2026.
ABSTRACT Aim The gut microbiome modulates immune responses, and butyrate‐producing bacteria have been linked to improved immune checkpoint inhibitor (ICI) efficacy. Conversely, proton pump inhibitors (PPIs) may negatively impact ICI outcomes by altering gut microbiota.
Kazuhiro Nouso   +34 more
wiley   +1 more source

Therapeutic Monitoring of Patients With Hereditary Tyrosinemia Type 1—A Belgian Monocentric Experience

open access: yesJIMD Reports, Volume 67, Issue 1, January 2026.
ABSTRACT Hereditary tyrosinemia type I (HT‐1) is a rare metabolic disorder treated by NTBC, requiring careful therapeutic and nutritional monitoring. While follow‐up traditionally relies on urinary succinylacetone, plasma NTBC and plasma amino acids, dried blood spot (DBS) methods have introduced alternative monitoring options.
Anne‐Sophie Adam   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy